Azaya Therapeutics, Inc Report issue

For profit Phase 1
Founded: San Antonio TX United States (2002)
Status: Acquired by Cytori Therapeutics (2017) → now Thermo Fisher Scientific (2017)

Organization Overview

First Clinical Trial
2009
NCT01041235
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Azaya Therapeutics, Inc. | Azaya Therapeutics, Inc (Medical Monitor)

Active Ingredients

Drugs in Phase 1 Trials (2)

docetaxel (taxotere) (1 trial)

doxorubicin (Doxil) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Ovarian Epithelial (Phase 1)

Genital Neoplasms, Female (Phase 1)

Ovarian Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 2